Preprint of results for Sinovac CoronaVac phase 1/2 trial in 3-17 year-olds: 72 in phase 1, 480 in phase 2. They tested half & full doses, & immune responses were higher than they are in adults, with a very low rate of adverse reactions ...1/n papers.ssrn.com/sol3/papers.cf…
...Firstly, it's clear why they have gone on to do another large study in under-18s (clinicaltrials.gov/ct2/show/NCT04…). The children were all Han ethnicity & they want to test in other parts of the country to get more diversity...2/n
...Although their results suggest for very small children, half-dose might have been enough, it didn't seem to reduce adverse reactions. That's presumably why the next trial is only full dose...3/4
..No adverse reactions caused concern. The only adverse event that was appreciably higher in vax than placebo groups, was injection site pain: 16% for vax, 2% for placebo.
Not clear if going to go onto a much larger study after the next phase 2 study, or study outside China. 4/4
Not clear if going to go onto a much larger study after the next phase 2 study, or study outside China. 4/4
• • •
Missing some Tweet in this thread? You can try to
force a refresh
